Eli Lilly’s Alzheimer’s Drug Donanemab Is Being Considered For FDA Approval—Here’s What To Know

This post was originally published on Forbes Middle East

A panel of experts advising the Food and Drug Administration could recommend Eli Lilly’s experimental Alzheimer’s drug donanemab for FDA approval, a closely watched decision that could pave the way for the drug to become the second of its kind authorized in the U.S.

…